| Literature DB >> 25995234 |
Stuart A Green1, Emmi Honeybourne2, Sylvia R Chalkley1, Alan J Poots1, Thomas Woodcock1, Geraint Price2, Derek Bell1, John Green3.
Abstract
OBJECTIVES: This study aims to identify patient and treatment factors that affect clinical outcomes of community psychological therapy through the development of a predictive model using historic data from 2 services in London. In addition, the study aims to assess the completeness of data collection, explore how treatment outcomes are discriminated using current criteria for classifying recovery, and assess the feasibility and need for undertaking a future larger population analysis.Entities:
Keywords: EPIDEMIOLOGY; MENTAL HEALTH
Mesh:
Year: 2015 PMID: 25995234 PMCID: PMC4442244 DOI: 10.1136/bmjopen-2014-006103
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Classification of treatment outcome combining final values of PHQ-9 and GAD-7
| Treatment outcome | Final PHQ-9 | Final GAD-7 | ||
|---|---|---|---|---|
| <10 | ≥10 | <8 | ≥8 | |
| P1P2 | Positive | Positive | ||
| P1N2 | Positive | Negative | ||
| N1P2 | Negative | Positive | ||
| N1N2 | Negative | Negative | ||
GAD-7, Generalised Anxiety Disorder-7; N1P2, negative PHQ-9, positive GAD-7; N1N2, negative PHQ-9, negative GAD-7; PHQ-9, Patient Health Questionnaire-9; P1P2, positive PHQ-9, positive GAD-7; P1N2, positive PHQ-9, negative GAD-7.
Figure 1Flow diagram showing the organisation of procedures and the number of patients included at each stage of data cleaning and allocation of patients to outcome groups (GAD-7, Generalised Anxiety Disorder-7; IAPT, Improving Access to Psychological Therapies; N1P2, negative PHQ-9, positive GAD-7; N1N2, negative PHQ-9, negative GAD-7; PHQ-9, Patient Health Questionnaire-9; P1P2, positive PHQ-9, positive GAD-7; P1N2, positive PHQ-9, negative GAD-7).
Frequencies of categorical variables comparing services A and B
| Variable | Completeness of data recording (%) | Service A | Service B |
|---|---|---|---|
| N (%) | N (%) | ||
| Gender | 100 | 1098:2061 (35:65) | 445:787 (36:64) |
| Ethnicity | 93 | 1292:1438:131 (45:50:5) | 361:776:95 (29:63:8) |
| Able to communicate in spoken English? | 91 | 2828:39:32 (98.3:0.9:0.9) | 1048:39:18 (94.8:3.5:1.6) |
| Understand written English? | 90 | 2828:39:32 (97.6:1.3:1.1) | 972:43:43 (91.9:4.1:4.1) |
| Source of Referral | 100 | 2268:656:236 (71.8:20.8:7.5) | 1157:2:73 (93.9:0.2:5.9) |
| Caseness threshold met | 100 | 2130:1029 (67.4:32.6) | 885:347 (71.8:28.2) |
| GSH | 100 | 2110:1050 (66.8:33.2) | 455:777 (36.9:63.1) |
| CBT | 100 | 1651:1509 (52.2:47.8) | 822:410 (66.7:33.3) |
BME, black and minority ethnic; CBT, cognitive–behavioural therapy; GSH, guided self-help.
Descriptive statistics for numeric variables for services A and B
| Completeness of data recording (%) | Service | n | Minimum | Maximum | Mean | SD | |
|---|---|---|---|---|---|---|---|
| Age | 100 | A | 3159 | 17 | 100 | 38.3 | 13.3 |
| B | 1232 | 12 | 95 | 38.2 | 12.7 | ||
| Length of treatment (days) | 100 | A | 3160 | 0 | 571 | 104.5 | 86.1 |
| B | 1232 | 0 | 409 | 96.6 | 79.0 | ||
| DNA sessions (n) | 100 | A | 3160 | 0 | 12 | 0.71 | 1.2 |
| B | 1232 | 0 | 9 | 0.8 | 1.2 | ||
| Attended sessions (n) | 100 | A | 3160 | 1 | 33 | 7.5 | 5.4 |
| B | 1232 | 1 | 30 | 6.5 | 4.6 | ||
| PHQ9 first score | 100 | A | 3160 | 0 | 27 | 14.3 | 6.5 |
| B | 1232 | 0 | 27 | 15.4 | 6.8 | ||
| PHQ9 last score | 100 | A | 3160 | 0 | 27 | 9.2 | 6.9 |
| B | 1232 | 0 | 27 | 10.9 | 7.4 | ||
| GAD-7 first score | 100 | A | 3158 | 0 | 21 | 12.6 | 5.6 |
| B | 1232 | 0 | 21 | 13.4 | 5.5 | ||
| GAD-7 last score | 100 | A | 3160 | 0 | 21 | 8.3 | 6.0 |
| B | 1232 | 0 | 21 | 9.7 | 6.2 | ||
| IMD | 98.2 | A | 3095 | 1.4 | 69.7 | 27.1 | 12.6 |
| B | 1221 | 9.7 | 61.4 | 29.9 | 11.2 |
DNA, sessions not attended; GAD-7, Generalised Anxiety Disorder-7; IMD, Index of Multiple Deprivation; PHQ9, Patient Health Questionnaire-9.
Descriptive statistics for numeric variables for each treatment outcome
| Pre-treatment/post- treatment variable | Variable | Treatment outcome | n | Minimum | Maximum | Mean | SD |
|---|---|---|---|---|---|---|---|
| Pre-treatment | Age | P1P2 | 2001 | 17 | 86 | 37.86 | 13.36 |
| P1N2 | 440 | 18 | 88 | 36.67 | 13.42 | ||
| N1P2 | 222 | 17 | 83 | 40.17 | 14.97 | ||
| N1N2 | 1728 | 12 | 100 | 38.92 | 12.51 | ||
| Pre-treatment | PHQ9 1st score | P1P2 | 2001 | 0 | 27 | 11.7 | 6.3 |
| P1N2 | 440 | 1 | 27 | 13.0 | 5.8 | ||
| N1P2 | 222 | 0 | 27 | 15.9 | 5.3 | ||
| N1N2 | 1729 | 0 | 27 | 18.3 | 5.3 | ||
| Pre-treatment | GAD-7 1st score | P1P2 | 2000 | 0 | 21 | 10.6 | 5.5 |
| P1N2 | 439 | 0 | 21 | 13.6 | 4.7 | ||
| N1P2 | 222 | 0 | 21 | 11.1 | 5.4 | ||
| N1N2 | 1729 | 0 | 21 | 15.6 | 4.4 | ||
| Pre-treatment | IMD | P1P2 | 1971 | 1.4 | 61.4 | 26.39 | 11.72 |
| P1N2 | 426 | 2.4 | 61.4 | 26.69 | 12.04 | ||
| N1P2 | 217 | 4.0 | 61.4 | 27.38 | 12.79 | ||
| N1N2 | 1702 | 3.1 | 69.7 | 29.94 | 12.66 | ||
| Post-treatment | Length of treatment (days) | P1P2 | 1825 | 3 | 571 | 121.64 | 78.15 |
| P1N2 | 371 | 5 | 510 | 130.18 | 91.35 | ||
| N1P2 | 196 | 1 | 454 | 108.57 | 80.67 | ||
| N1N2 | 1448 | 1 | 482 | 108.94 | 79.06 | ||
| Post-treatment | Number of sessions not attended | P1P2 | 2001 | 0 | 9 | 0.55 | 0.98 |
| P1N2 | 440 | 0 | 7 | 0.66 | 1.07 | ||
| N1P2 | 222 | 0 | 6 | 0.85 | 1.11 | ||
| N1N2 | 1729 | 0 | 12 | 0.97 | 1.31 | ||
| Post-treatment | Number of sessions attended | P1P2 | 2001 | 1 | 32 | 8.01 | 5.13 |
| P1N2 | 440 | 1 | 32 | 7.14 | 5.54 | ||
| N1P2 | 222 | 1 | 28 | 6.19 | 4.76 | ||
| N1N2 | 1729 | 1 | 33 | 6.41 | 5.18 |
GAD-7, Generalised Anxiety Disorder-7; IMD, Index of Multiple Deprivation; N1P2, negative PHQ-9, positive GAD-7; N1N2, negative PHQ-9, negative GAD-7; P1P2, positive PHQ-9, positive GAD-7; P1N2, positive PHQ-9, negative GAD-7; PHQ9, Patient Health Questionnaire-9.
Grading from lowest to highest numerical levels for pre-treatment and post-treatment variables
| Pre-treatment/post- treatment variable | Variable | Grading in order from lowest to highest level | |||
|---|---|---|---|---|---|
| 1st | 2nd | 3rd | 4th | ||
| Pre-treatment | Age | P1N2 | P1P2 | N1N2 | N1P2 |
| Pre-treatment | PHQ-9 1st score | P1P2 | P1N2 | N1P2 | N1N2 |
| Pre-treatment | GAD-7 1st score | P1P2 | N1P2 | P1N2 | N1N2 |
| Pre-treatment | IMD | P1P2 | P1N2 | N1P2 | N1N2 |
| Post-treatment | LoT (days) | N1P2 | N1N2 | P1P2 | P1N2 |
| Post-treatment | Number of DNA sessions | P1P2 | P1N2 | N1P2 | N1N2 |
| Post-treatment | Number of Attended sessions | N1P2 | N1N2 | P1N2 | P1P2 |
GAD7, Generalised Anxiety Disorder-7; IMD, Index of Multiple Deprivation; LoT, length of treatment; N1P2, negative PHQ-9, positive GAD-7; N1N2, negative PHQ-9, negative GAD-7; P1P2, positive PHQ-9, positive GAD-7; P1N2, positive PHQ-9, negative GAD-7; PHQ9, Patient Health Questionnaire-9.
Outcome Group 1 classification results for predictive model created using pre-treatment variables
| Classification results | ||||
|---|---|---|---|---|
| Treatment outcome | Predicted group membership | Total (%) | ||
| P1P2 (%) | N1N2 (%) | |||
| Cases selected | ||||
| Original (71.8%) | P1P2 | 30.1 | 100.0 | |
| N1N2 | 25.9 | 100.0 | ||
| Cross-validated (71.6%) | P1P2 | 30.1 | 100.0 | |
| N1N2 | 26.2 | 100.0 | ||
| Cases not selected | ||||
| Original (74.9%) | P1P2 | 26.1 | 100.0 | |
| N1N2 | 24.0 | 100.0 | ||
GAD7, Generalised Anxiety Disorder-7; N1P2, negative PHQ-9, positive GAD-7; N1N2, negative PHQ-9, negative GAD-7; P1P2, positive PHQ-9, positive GAD-7; P1N2, positive PHQ-9, negative GAD-7; PHQ9, Patient Health Questionnaire-9.
Contributions of individual pre-treatment variables to the model created to predict outcomes for the model for predicting outcomes within Outcome Group 1
| Tests of equality of group means | |||
|---|---|---|---|
| Order of Importance | Variables | Wilks’ λ | Significance |
| 1 | PHQ-9 first | 0.794 | <0.001 |
| 2 | GAD-7 first score | 0.823 | <0.001 |
| 3 | Caseness achieved | 0.849 | <0.001 |
| 4 | IMD | 0.976 | <0.001 |
| 5 | Ethnicity | 0.987 | <0.001 |
| 6 | Age | 0.995 | 0.005 |
| 7 | Source of referral (coded) | 0.996 | 0.010 |
| 8 | Gender | 0.997 | 0.039 |
| 9 | Understand written English? | 0.998 | 0.058 |
GAD7, Generalised Anxiety Disorder-7; IMD, Index of Multiple Deprivation; PHQ9, Patient Health Questionnaire-9.
Outcome Group 2 classification results for predictive model created using pre-treatment variables
| Classification results | ||||
|---|---|---|---|---|
| Treatment outcome | Predicted group membership | Total (%) | ||
| P1P2 (%) | N and partial N (%) | |||
| Cases selected | ||||
| Original (68.5%) | P1P2 | 32.8 | 100.0 | |
| P1N2, N1P2 and N1N2 | 30.3 | 100.0 | ||
| Cross-validated (68.3%) | P1P2 | 33.2 | 100.0 | |
| P1N2, N1P2 and N1N2 | 30.4 | 100.0 | ||
| Cases not selected | ||||
| Original (70.9%) | P1P2 | 29.0 | 100.0 | |
| P1N2, N1P2 and N1N2 | 29.3 | 100.0 | ||
GAD7, Generalised Anxiety Disorder-7; N1P2, negative PHQ-9, positive GAD-7; N1N2, negative PHQ-9, negative GAD-7; P1P2, positive PHQ-9, positive GAD-7; P1N2, positive PHQ-9, negative GAD-7; PHQ9, Patient Health Questionnaire-9.
Contributions of individual pre-treatment variables to the model created to predict outcomes for the model for predicting outcomes within Outcome Group 2
| Tests of equality of group means | |||
|---|---|---|---|
| Order of importance | Variable | Wilks’ λ | Significance |
| 1 | PHQ-9 first score | 0.846 | <0.001 |
| 2 | GAD-7 first score | 0.858 | <0.001 |
| 3 | IMD | 0.986 | <0.001 |
| 4 | Ethnicity | 0.992 | <0.001 |
| 5 | Understand written English? | 0.998 | 0.036 |
| 6 | Gender | 0.999 | 0.045 |
| 7 | Age | 0.999 | 0.077 |
GAD7, Generalised Anxiety Disorder-7; IMD, Index of Multiple Deprivation; PHQ9, Patient Health Questionnaire-9.
Outcome Group 2 classification results for predictive model created using pre-treatment and post-treatment variables
| Classification results | ||||
|---|---|---|---|---|
| Treatment outcome | Predicted group membership | Total | ||
| P1P2 (%) | N and partial N (%) | |||
| Cases selected | ||||
| Original (70.7%) | P1P2 | 28.6 | 100.0 | |
| P1N2, N1P2 and N1N2 | 30.0 | 100.0 | ||
| Cross-validated (70.2%) | P1P2 | 70.9 | 29.1 | 100.0 |
| P1N2, N1P2 and N1N2 | 30.4 | 100.0 | ||
| Cases not selected | ||||
| Original (71.3%) | P1P2 | 30.7 | 100.0 | |
| P1N2, N1P2 and N1N2 | 26.8 | 100.0 | ||
GAD7, Generalised Anxiety Disorder-7; N1N2, negative PHQ-9, negative GAD-7; N1P2, negative PHQ-9, positive GAD-7; P1P2, positive PHQ-9, positive GAD-7; P1N2, positive PHQ-9, negative GAD-7; PHQ9, Patient Health Questionnaire-9.
Contributions of individual pre-treatment and post-treatment variables to the model created to predict outcomes for the model for predicting outcomes within Outcome Group 1
| Tests of equality of group means | |||
|---|---|---|---|
| Order of importance | Variables | Wilks’ λ | Significance |
| 1 | PHQ9 1st score | 0.842 | <0.001 |
| 2 | GAD7 1st score | 0.865 | <0.001 |
| 3 | No. DNA sessions | 0.974 | <0.001 |
| 4 | No. attended sessions | 0.981 | <0.001 |
| 5 | IMD | 0.987 | <0.001 |
| 6 | Ethnicity | 0.992 | <0.001 |
| 7 | Length of treatment in days | 0.998 | 0.041 |
| 8 | Cognitive–behavioural therapy | 0.998 | 0.037 |
| 9 | Understand written English? | 0.998 | 0.057 |
| 10 | Guided self help | 0.999 | 0.077 |
| 11 | Gender | 0.999 | 0.087 |
GAD7, Generalised Anxiety Disorder-7; IMD, Index of Multiple Deprivation; PHQ9, Patient Health Questionnaire-9.
Outcome Group 3 classification results for predictive model created using pre-treatment variables
| Classification results | ||||||
|---|---|---|---|---|---|---|
| Treatment outcome | Predicted group membership | Total | ||||
| P1P2 | P1N2 | N1P2 | N1N2 | |||
| Cases selected | ||||||
| Original | P1P2 | 23.7 | 20.4 | 15.5 | 100.0 | |
| P1N2 | 22.5 | 9.3 | 25.6 | 100.0 | ||
| N1P2 | 19.1 | 9.2 | 31.3 | 100.0 | ||
| N1N2 | 9.5 | 19.8 | 18.5 | 100.0 | ||
| Cross-validated | P1P2 | 23.8 | 20.4 | 15.5 | 100.0 | |
| P1N2 | 22.5 | 9.3 | 26.0 | 100.0 | ||
| N1P2 | 20.6 | 9.2 | 31.3 | 100.0 | ||
| N1N2 | 9.5 | 20.1 | 18.7 | 100.0 | ||
| Cases not selected | ||||||
| Original | P1P2 | 24.4 | 19.8 | 15.0 | 100.0 | |
| P1N2 | 21.9 | 11.5 | 18.8 | 100.0 | ||
| N1P2 | 17.2 | 6.3 | 20.3 | 100.0 | ||
| N1N2 | 11.4 | 18.3 | 19.6 | 100.0 | ||
GAD7, Generalised Anxiety Disorder-7; N1P2, negative PHQ-9, positive GAD-7; N1N2, negative PHQ-9, negative GAD-7; P1P2, positive PHQ-9, positive GAD-7; P1N2, positive PHQ-9, negative GAD-7; PHQ9, Patient Health Questionnaire-9.